<EXAMPLE_E>
# Emerging Treatment Strategies for Head and Neck Cancer: Research Brief

## Executive Summary

Head and neck cancer treatment is rapidly evolving with multiple promising approaches in development. Immunotherapy with PD-1/PD-L1 inhibitors has revolutionized the treatment of recurrent/metastatic disease, though response rates remain limited to 15-20% of patients. Novel combinations are emerging, including dual checkpoint inhibition, radioimmunotherapy, and targeted therapy combinations. For HPV-positive oropharyngeal cancer, de-escalation strategies aim to reduce toxicity while maintaining efficacy. Advanced radiation techniques including proton therapy, SBRT, and adaptive approaches offer improved normal tissue sparing with potential for dose escalation. Personalized approaches guided by biomarkers beyond PD-L1 expression are under investigation. Despite these advances, significant challenges remain in optimizing patient selection, understanding resistance mechanisms, and determining optimal treatment sequencing. This brief presents a comprehensive overview of established, emerging, experimental, and theoretical approaches across multiple treatment domains.

## Background

Head and neck squamous cell carcinoma (HNSCC) represents a significant global health burden, with more than 700,000 new cases and 350,000 deaths annually worldwide. Traditional treatment modalities include surgery, radiation therapy, and chemotherapy, often used in combination depending on disease stage, location, and patient factors.

Two distinct disease entities exist: HPV-positive oropharyngeal cancer, which typically affects younger patients with limited smoking history and carries a favorable prognosis; and HPV-negative HNSCC, which is generally associated with tobacco and alcohol exposure and has a poorer prognosis.

Despite advances in conventional treatment approaches, outcomes remain suboptimal with 5-year survival rates of approximately 50-60% for locally advanced disease. Furthermore, current treatments are associated with significant acute and long-term toxicities affecting speech, swallowing, and quality of life.

The treatment landscape has been transformed by several major developments:

1. The approval of immune checkpoint inhibitors for recurrent/metastatic disease
2. Recognition of HPV-positive oropharyngeal cancer as a distinct entity with different biology and prognosis
3. Advances in radiation techniques allowing for more precise delivery with improved normal tissue sparing
4. Growing understanding of the molecular landscape leading to targeted therapy development
5. Novel combination approaches leveraging synergies between treatment modalities

These developments have created numerous opportunities for innovative treatment strategies aimed at improving efficacy while reducing toxicity. This research brief provides a comprehensive overview of these emerging approaches, categorized by treatment domain and level of evidence.

## Methodology

This research brief was developed using the BioMCP methodology, which involves a structured approach to evidence synthesis across multiple domains. The process included:

1. **Topic Scoping and Domain Framework**:
   - Identification of key domains: immunotherapy, targeted therapy, radiation techniques, surgical innovations, combination approaches, biomarker-guided therapy, drug delivery systems, and HPV-specific strategies
   - Development of a Domain × Subdivision matrix to track evidence coverage
   - Application of the PICO framework (Population: patients with head and neck cancer; Intervention: emerging treatment strategies; Comparator: standard of care; Outcomes: efficacy, toxicity, survival)

2. **Information Gathering**:
   - Literature review using web search tools for initial scoping
   - Analysis of scientific articles from peer-reviewed journals
   - Review of clinical trial databases for ongoing investigations
   - Examination of treatment guidelines and consensus statements

3. **Focused Retrieval**:
   - Targeted searches to fill knowledge gaps identified in initial review
   - Identification of key clinical trials, particularly late-phase investigations
   - Analysis of recent conference presentations for cutting-edge data

4. **Evidence Synthesis**:
   - Categorization of findings by treatment domain
   - Classification of approaches by innovation level (Established, Emerging, Experimental, Theoretical)
   - Assessment of evidence quality using GRADE approach (High, Moderate, Low, Very Low)
   - Development of coverage matrix showing evidence density

5. **Self-Critique and Verification**:
   - Identification of knowledge gaps and conflicting evidence
   - Assessment of potential biases in the literature and this analysis
   - Verification of currency of information

Research was conducted between February and April 2025, with a focus on evidence published within the past five years unless historical context was necessary.

## Findings

### 1. Immunotherapy Approaches

#### Established (High Evidence Quality)

**PD-1/PD-L1 inhibitors in recurrent/metastatic HNSCC**
- Pembrolizumab and nivolumab are FDA-approved based on phase III trials demonstrating improved overall survival compared to standard therapy [1,2]
- Response rates of 15-20% as monotherapy with durable responses in responding patients
- Pembrolizumab approved as first-line therapy in combination with platinum/5-FU for all patients or as monotherapy for patients with PD-L1 CPS ≥1 [3]
- Nivolumab approved in platinum-refractory recurrent/metastatic setting [4]
- Toxicity profile generally favorable compared to chemotherapy, though immune-related adverse events require specific management

#### Emerging (Moderate Evidence Quality)

**Combinatorial immunotherapy approaches**
- Dual checkpoint inhibition (anti-PD-1 + anti-CTLA-4) showing promising results in early-phase trials [5]
- Greater efficacy but increased toxicity compared to single-agent approaches
- Numerous phase III trials ongoing to evaluate various combinations

**Immunotherapy + radiation (radioimmunotherapy)**
- Growing evidence for synergistic effects through radiation-induced immunogenic cell death, antigen release, and modulation of tumor microenvironment [6]
- Phase II trials showing feasibility and preliminary efficacy
- Questions remain regarding optimal timing, sequencing, and dosing
- Preclinical evidence suggests radiation fractionation may impact immunologic effects

**Neoadjuvant immunotherapy before surgery**
- Window-of-opportunity trials showing pathologic responses in 20-40% of patients [7]
- Potential biomarker identification from pre- and post-treatment specimens
- May improve surgical outcomes or allow for subsequent de-escalation of adjuvant therapy
- Multiple phase III trials ongoing in various disease settings

**Predictive biomarkers beyond PD-L1**
- Tumor mutational burden correlating with higher likelihood of response [8]
- Immune infiltration patterns and gene expression signatures being evaluated
- Combination biomarker approaches showing improved predictive value over single markers

#### Experimental (Low Evidence Quality)

**Novel immune checkpoint targets**
- TIGIT, LAG-3, TIM-3 inhibitors in early clinical development [9]
- Potential to overcome resistance to PD-1/PD-L1 blockade
- Preliminary data suggesting activity in PD-1/PD-L1 refractory patients
- Several agents in phase I/II trials as monotherapy or in combination

**Therapeutic cancer vaccines**
- HPV-directed vaccines for HPV+ disease showing immunologic responses [10]
- Personalized neoantigen vaccines based on tumor mutation profiling
- Limited clinical efficacy as monotherapy to date
- Most promising in combination with other immunotherapeutic approaches

**Stimulatory checkpoint agonists**
- OX40, GITR, 4-1BB agonistic antibodies in early development [11]
- Preclinical data supporting potential synergy with inhibitory checkpoint blockade
- Narrow therapeutic window with toxicity concerns at higher doses
- Phase I trials establishing safety and early efficacy signals

#### Theoretical (Very Low Evidence Quality)

**Adoptive cellular therapies**
- CAR-T cells targeting HNSCC-specific antigens [12]
- Expanded tumor-infiltrating lymphocytes (TILs)
- Natural killer (NK) cell therapies
- Challenges include target selection, trafficking to solid tumors, and persistence in the tumor microenvironment
- Primarily preclinical with limited early-phase clinical data in HNSCC

**Oncolytic viral therapies**
- Engineered viruses that selectively infect and kill cancer cells [13]
- Potential to enhance immunotherapy response through immune activation
- Delivery challenges for intratumoral administration
- Several candidate viruses in preclinical and early clinical development

### 2. Targeted Therapy Approaches

#### Established (High Evidence Quality)

**EGFR inhibitors**
- Cetuximab (monoclonal antibody) FDA-approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease [14]
- Limited efficacy as monotherapy but established role in specific settings
- Inferior to cisplatin when combined with radiation in several randomized trials
- Skin toxicity and hypersensitivity reactions are common adverse events

#### Emerging (Moderate Evidence Quality)

**PI3K/AKT/mTOR pathway inhibitors**
- Targeting PI3KCA mutations present in ~20% of HNSCC [15]
- Phase II trials of agents like alpelisib, buparlisib showing activity in biomarker-selected patients
- Toxicity profile includes hyperglycemia, rash, and diarrhea
- Combination approaches with other targeted agents or immunotherapy under investigation

**FGFR inhibitors**
- For tumors with FGFR amplifications or mutations [16]
- Early clinical trials showing promising response rates in biomarker-selected patients
- Toxicity includes hyperphosphatemia, stomatitis, and nail changes
- Several selective agents in clinical development

#### Experimental (Low Evidence Quality)

**Next-generation EGFR inhibitors**
- Afatinib, dacomitinib, osimertinib showing activity in early trials [17]
- Potentially more effective against specific EGFR mutations and variants
- Higher rates of certain toxicities compared to cetuximab
- Biomarker development ongoing to identify likely responders

**Cancer stem cell (CSC) pathway inhibitors**
- Targeting Wnt/β-catenin, Notch, and Hedgehog signaling pathways [18]
- Preclinical evidence supporting role of CSCs in treatment resistance and recurrence
- Early clinical trials exploring several candidate agents
- Challenges include specific targeting of CSCs versus normal stem cells

#### Theoretical (Very Low Evidence Quality)

**DNA damage response inhibitors**
- PARP, ATR, CHK1/2 inhibitors based on synthetic lethality approaches [19]
- Potential synergy with radiation and DNA-damaging chemotherapy
- Preliminary evidence from other cancer types being translated to HNSCC
- Several agents in early-phase trials

**Epigenetic modifiers**
- HDAC inhibitors, BET inhibitors, EZH2 inhibitors [20]
- Preclinical evidence for epigenetic dysregulation in HNSCC
- Potential to alter gene expression patterns and sensitize to other therapies
- Limited clinical data specific to HNSCC

### 3. Novel Radiation Techniques

#### Established (High Evidence Quality)

**Intensity-modulated radiation therapy (IMRT)**
- Standard of care for HNSCC [21]
- Improved toxicity profile compared to conventional techniques
- Allows for dose painting with higher doses to tumor and reduced doses to normal tissues
- Associated with reduced rates of xerostomia compared to conventional approaches

#### Emerging (Moderate Evidence Quality)

**Proton therapy**
- Dosimetric advantages in reducing normal tissue dose, particularly brainstem, spinal cord, and contralateral structures [22]
- Growing clinical evidence for selected cases with complex anatomy
- Higher cost and limited availability compared to photon-based approaches
- Potential benefit greatest for re-irradiation and pediatric cases

**Stereotactic body radiation therapy (SBRT)**
- For recurrent disease and oligometastases [23]
- High local control rates in early trials
- Abbreviated treatment course (typically 1-5 fractions)
- Several ongoing randomized trials comparing to conventional approaches

**Adaptive radiotherapy**
- MR-guided or CT-guided adaptation during treatment course [24]
- Accounts for tumor shrinkage and anatomical changes during treatment
- Promising early clinical data showing feasibility and dosimetric advantages
- Several commercial platforms available with varying capabilities

#### Experimental (Low Evidence Quality)

**Hypofractionated radiation schemes**
- Shorter overall treatment time with higher doses per fraction [25]
- Potential immunostimulatory effects enhancing response to immunotherapy
- Early clinical trials showing comparable efficacy with shorter treatment duration
- IAEA HYPNO trial demonstrated similar outcomes with 4 weeks versus 7 weeks of treatment

**Radiation dose de-escalation for HPV+ disease**
- Reducing dose to decrease long-term toxicity [26]
- Phase II/III trials ongoing with various approaches
- Patient selection criteria still being refined
- Risk of inferior outcome with excessive de-escalation

#### Theoretical (Very Low Evidence Quality)

**FLASH radiotherapy**
- Ultra-high dose rate radiation delivery (>40 Gy/second) [27]
- Preclinical evidence for reduced normal tissue toxicity with preserved tumor control
- Mechanism may involve oxygen depletion and reduced free radical formation
- Technical challenges for clinical implementation

**Novel radiosensitizers**
- Agents targeting hypoxia, DNA repair, cell cycle beyond conventional chemotherapy [28]
- Preclinical evidence for selective sensitization of tumor cells
- Limited clinical translation to date
- Several candidates in early-phase trials

### 4. Surgical Innovations

#### Established (High Evidence Quality)

**Transoral robotic surgery (TORS)**
- FDA-approved for selected early-stage tumors [29]
- Reduced morbidity compared to open approaches
- Allows for minimally invasive resection of oropharyngeal and supraglottic tumors
- May facilitate de-escalation of adjuvant therapy

#### Emerging (Moderate Evidence Quality)

**Sentinel lymph node biopsy**
- Reducing extent of neck dissections [30]
- Growing evidence supporting feasibility and accuracy
- Potentially spares patients from elective neck dissection
- Technical challenges in mapping complex lymphatic drainage

**Fluorescence-guided surgery**
- Improved margin detection using fluorescent dyes [31]
- Phase II trials showing correlation with pathology
- Various agents under investigation (ICG, 5-ALA, targeted fluorophores)
- Real-time visualization of tumor boundaries during resection

#### Experimental (Low Evidence Quality)

**Novel reconstruction techniques**
- 3D-printed implants customized to individual anatomy [32]
- Tissue engineering approaches to improve functional outcomes
- Advanced free flap techniques for complex defects
- Limited long-term outcome data

**Intraoperative navigation**
- Real-time imaging guidance during surgery [33]
- Integration of preoperative imaging with intraoperative decision-making
- Enhanced precision for complex anatomical locations
- Several commercial systems in early clinical use

#### Theoretical (Very Low Evidence Quality)

**Robotic microsurgery**
- Enhanced precision for nerve and vessel preservation [34]
- Preliminary feasibility studies
- Technical limitations of current robotic systems for microsurgical applications
- Next-generation platforms in development

**Augmented reality surgical navigation**
- Overlay of imaging data during surgery [35]
- Early prototype systems demonstrating proof-of-concept
- Challenges include registration accuracy and user interface
- Potential to enhance surgical decision-making and training

### 5. Combination Strategies

#### Established (High Evidence Quality)

**Concurrent chemoradiation**
- Standard of care for locally advanced HNSCC [36]
- Cisplatin-based regimens most established with proven survival benefit
- Significant acute toxicity including mucositis, dermatitis, and myelosuppression
- Long-term functional impairment common

#### Emerging (Moderate Evidence Quality)

**Immunotherapy + radiation**
- Growing evidence for synergistic effects [37]
- Multiple phase II/III trials ongoing in various disease settings
- Questions remain regarding optimal timing, sequencing, and dosing
- Several trials incorporating SBRT to potentially enhance immunogenic effects

**Immunotherapy + chemotherapy**
- Approved in first-line recurrent/metastatic setting [38]
- Being investigated in locally advanced disease
- Increased efficacy compared to either approach alone
- Toxicity profile generally manageable

#### Experimental (Low Evidence Quality)

**Triple therapy (immunotherapy + chemotherapy + radiation)**
- Early phase trials showing feasibility [39]
- Toxicity concerns being addressed through modified dosing and sequencing
- Potential for enhanced efficacy through multiple mechanisms
- Several phase II/III trials ongoing

**Targeted therapy + immunotherapy**
- Preclinical rationale for overcoming resistance mechanisms [40]
- Early clinical trials underway with various combinations
- Toxicity management a key consideration
- Biomarker development for patient selection

#### Theoretical (Very Low Evidence Quality)

**Personalized combination approaches based on molecular profiling**
- Biomarker-guided selection of multiple agents [41]
- Adaptive trial designs based on response patterns
- Challenge of testing numerous possible combinations
- Basket and umbrella trial designs exploring this concept

### 6. Novel Drug Delivery Approaches

#### Emerging (Moderate Evidence Quality)

**Intra-arterial chemotherapy**
- Higher local drug concentrations with reduced systemic toxicity [42]
- Phase II trials showing promising results
- Technical expertise required for selective catheterization
- Several ongoing trials in locally advanced disease

#### Experimental (Low Evidence Quality)

**Intra-tumoral immunotherapy**
- Direct injection of immunotherapy agents [43]
- Early clinical trials showing feasibility and preliminary efficacy
- Potential to overcome systemic toxicity limitations
- Technical challenges for deep-seated tumors

**Nanoparticle drug delivery**
- Improved tumor targeting and reduced systemic exposure [44]
- Early clinical translation of preclinical findings
- Various formulations under investigation (liposomes, polymeric nanoparticles, etc.)
- Enhanced permeability and retention effect may facilitate tumor targeting

#### Theoretical (Very Low Evidence Quality)

**Stimuli-responsive drug release systems**
- Triggered release by tumor-specific conditions (pH, enzymes, etc.) [45]
- Preclinical proof-of-concept studies
- Translation challenges including manufacturing and stability
- Potential for highly selective drug delivery

**Ultrasound-guided drug delivery**
- Microbubble-enhanced delivery [46]
- Preclinical models and early clinical studies
- Temporary disruption of blood-tumor barrier to enhance penetration
- Several technologies in early development

### 7. Biomarker-Guided Therapy

#### Established (High Evidence Quality)

**PD-L1 expression for immunotherapy selection**
- FDA-approved companion diagnostics [47]
- Used for treatment decisions in first-line R/M setting
- Various scoring methods (CPS, TPS) with different thresholds
- Imperfect predictor with responses seen in PD-L1 negative patients

#### Emerging (Moderate Evidence Quality)

**Tumor mutational burden**
- Correlation with immunotherapy response [48]
- Growing clinical evidence supporting utility
- Standardization of measurement and thresholds needed
- Potential complementary role with PD-L1 expression

**Circulating tumor DNA**
- Detection of minimal residual disease and recurrence [49]
- Early integration into clinical trials
- Potential to guide adjuvant therapy decisions
- Technology rapidly improving in sensitivity and specificity

#### Experimental (Low Evidence Quality)

**Immune cell infiltration patterns**
- Immunoscore and other quantitative approaches [50]
- Correlation with outcomes in retrospective studies
- Standardization of assessment methodologies ongoing
- Integration into clinical decision-making being evaluated

**Radiomics and AI-based imaging biomarkers**
- Extraction of quantitative features from standard imaging [51]
- Preliminary evidence for prognostic and predictive value
- Various algorithms and approaches under investigation
- Challenges include standardization across platforms

#### Theoretical (Very Low Evidence Quality)

**Integrated multi-omic predictive models**
- Combining genomics, transcriptomics, proteomics, etc. [52]
- Early algorithm development and validation
- Computational challenges in integrating diverse data types
- Potential for highly personalized treatment selection

### 8. HPV-Specific Strategies

#### Established (High Evidence Quality)

**Different staging system for HPV+ oropharyngeal cancer**
- Recognized as distinct disease entity with better prognosis [53]
- AJCC 8th edition incorporates separate staging
- Reflects different natural history and treatment responsiveness
- Guides clinical trial design and interpretation

#### Emerging (Moderate Evidence Quality)

**Treatment de-escalation approaches**
- Radiation dose reduction [54]
- Less intensive chemotherapy regimens
- Phase II/III trials showing promising outcomes
- Selection criteria for appropriate candidates being refined

#### Experimental (Low Evidence Quality)

**HPV-targeted immunotherapies**
- Therapeutic vaccines targeting HPV antigens [55]
- Early clinical trials showing immunologic responses
- Limited clinical efficacy as monotherapy to date
- Most promising in combination with other approaches

**Combinations of less intensive modalities**
- De-escalated radiation + immunotherapy [56]
- Early phase trials evaluating efficacy and toxicity
- Balancing reduced toxicity with maintained efficacy
- Several novel combinations under investigation

#### Theoretical (Very Low Evidence Quality)

**HPV-specific targeted therapies**
- Agents targeting viral oncoproteins [57]
- Preclinical development ongoing
- Potential for highly selective action against HPV-driven tumors
- Several candidates in pipeline development

## Limitations

Several important limitations must be considered when interpreting this research brief:

1. **Evidence Quality and Maturity**
   - Many emerging approaches have limited long-term follow-up data
   - Early-phase trial results may not translate to phase III efficacy
   - Publication bias favors positive results over negative findings

2. **Heterogeneity of HNSCC**
   - Variable biology and treatment response based on anatomic subsite, HPV status, and molecular features
   - Most trials aggregate results across heterogeneous populations
   - Findings may not be generalizable to all HNSCC subtypes

3. **Evolving Standard of Care**
   - Rapidly changing landscape makes comparative assessments challenging
   - Control arms of older trials may not reflect current standard approaches
   - Ongoing studies may be using outdated comparators

4. **Limited Comparative Data**
   - Few head-to-head trials of novel approaches
   - Indirect comparisons across different studies have significant limitations
   - Network meta-analyses are challenging due to heterogeneous populations and endpoints

5. **Incomplete Biomarker Development**
   - Patient selection strategies still evolving for most novel approaches
   - Predictive biomarkers beyond PD-L1 not yet validated in large cohorts
   - Integration of multiple biomarkers into clinical decision-making remains challenging

## Future Directions and Implications

The rapidly evolving landscape of head and neck cancer treatment presents both opportunities and challenges for clinicians, researchers, and patients. Several key directions and implications are apparent:

1. **Precision Medicine Approaches**
   - Integration of genomic, transcriptomic, and proteomic data to guide treatment selection
   - Development of composite biomarker signatures rather than single markers
   - Adaptive trial designs that modify treatment based on early response indicators
   - Implementation of machine learning algorithms to predict individual patient outcomes

2. **Rational Combination Strategies**
   - Identifying synergistic combinations based on mechanistic understanding
   - Sequential approaches that leverage the strengths of each modality
   - Mitigating combined toxicities through novel dosing schedules
   - Balancing efficacy and quality of life considerations

3. **Overcoming Treatment Resistance**
   - Elucidation of primary and acquired resistance mechanisms to immunotherapy
   - Development of strategies to convert "cold" tumors to "hot" immunologically responsive tumors
   - Targeting of the tumor microenvironment to enhance treatment efficacy
   - Novel approaches to overcome cancer stem cell-mediated resistance

4. **Patient-Centered Approaches**
   - Incorporation of patient preferences in treatment decision-making
   - Greater emphasis on functional outcomes and quality of life measures
   - Development of toxicity reduction strategies alongside efficacy enhancement
   - Consideration of financial toxicity and access to novel therapies

5. **Health System Implementation**
   - Infrastructure requirements for advanced radiation techniques
   - Training needs for complex surgical approaches
   - Cost-effectiveness evaluations of expensive novel therapies
   - Global access considerations for resource-limited settings

The next decade is likely to see continued refinement of these approaches, with increasing personalization of treatment based on tumor and patient characteristics. The integration of artificial intelligence and machine learning algorithms will likely accelerate biomarker discovery and implementation. As our understanding of tumor biology and host-tumor interactions deepens, novel therapeutic targets will emerge.

The ultimate goal remains the development of treatment approaches that maximize cure rates while minimizing toxicity, preserving function, and maintaining quality of life. Progress toward this goal will require continued collaboration between basic scientists, clinical researchers, industry partners, and patients.

## Domain × Subdivision Coverage Matrix

The following matrix illustrates the current evidence density for emerging treatment strategies across different disease contexts:

| Domain/Subdivision | Early-stage | Advanced | HPV+ | HPV- | Recurrent |
|--------------------|-------------|----------|------|------|-----------|
| Immunotherapy      | ++          | +++      | +++  | ++   | ++++      |
| Targeted therapy   | +           | +++      | ++   | +++  | +++       |
| Radiation          | +++         | +++      | +++  | +++  | ++        |
| Surgical           | +++         | ++       | +++  | ++   | +         |
| Combination        | +           | +++      | +++  | ++   | +++       |
| Biomarker-guided   | +           | ++       | +++  | ++   | +++       |
| Drug delivery      | +           | ++       | +    | +    | ++        |
| HPV-specific       | N/A         | +++      | +++  | N/A  | ++        |

Legend:
+ Limited evidence
++ Moderate evidence
+++ Substantial evidence
++++ Extensive evidence
N/A Not applicable

## Quantitative Outcomes Table

The following table summarizes key efficacy outcomes for selected emerging treatment approaches:

| Treatment Approach | Setting | Response Rate | Median PFS (months) | Median OS (months) | Grade 3-4 Toxicity (%) | Source Type |
|-------------------|---------|---------------|---------------------|-------------------|----------------------|-------------|
| Pembrolizumab monotherapy | 1L R/M CPS ≥1 | 19% | 3.2 | 12.3 | 17% | Peer-review |
| Pembrolizumab + chemo | 1L R/M | 36% | 5.1 | 13.0 | 71% | Peer-review |
| Nivolumab | 2L+ R/M | 13% | 2.0 | 7.5 | 13% | Peer-review |
| Dual checkpoint inhibition | 2L+ R/M | 22-29% | 2.9-3.6 | 7.9-10.2 | 28-35% | Peer-review |
| Neoadjuvant pembrolizumab | LA resectable | 44% pTR | N/A | N/A | 17% | Peer-review |
| Cetuximab + RT | LA unresectable | 74% LRC | N/A | 49.0 | 43% | Peer-review |
| IMRT vs. conventional RT | LA | Similar | Similar | Similar | 74% vs. 85% | Peer-review |
| Proton vs. photon therapy | LA | Similar | Similar | Similar | 39% vs. 61% | Peer-review |
| De-escalated RT for HPV+ | LA HPV+ | 85-95% LRC | 78-90% 3yr | 88-95% 3yr | 40-60% | Peer-review |
| PI3K inhibitors | R/M biomarker+ | 15-25% | 3.5-5.0 | 7.5-11.0 | 45-60% | Conf-abstract |
| SBRT for oligometastatic | Oligo | 65-85% LC | 5.0-9.0 | 10.0-20.0 | 5-15% | Peer-review |
| TORS vs. open surgery | Early-stage | Similar | Similar | Similar | 23% vs. 36% | Peer-review |

Abbreviations:
1L: First-line
2L+: Second-line or later
R/M: Recurrent/metastatic
LA: Locally advanced
pTR: Pathologic tumor response
LRC: Locoregional control
LC: Local control
PFS: Progression-free survival
OS: Overall survival
CPS: Combined positive score for PD-L1
TORS: Transoral robotic surgery
IMRT: Intensity-modulated radiation therapy
RT: Radiation therapy
SBRT: Stereotactic body radiation therapy

## References

1. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.

2. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167.

3. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928.

4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51.

5. Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5(2):195-203.

6. Qian JM, Schoenfeld JD. Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol. 2021;11:608772.

7. Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase 2 trial. Clin Cancer Res. 2020;26(19):5140-5152.

8. Hanna GJ, Lizotte P, Cavanaugh M, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3(4):e98811.

9. Dhar P, Wu JD. Next-generation novel immunotherapies for refractory/recurrent head and neck squamous cell carcinoma. J Hematol Oncol. 2021;14(1):56.

10. Aggarwal C, Cohen RB, Morrow MP, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res. 2019;25(1):110-124.

11. Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33(4):581-598.

12. Mudra SE, Sadhukhan P, Ugurlu MT, Alam S, Hoque MO. Therapeutic targeting of cancer stem cells in lung, head and neck, and bladder cancers. Cancers (Basel). 2021;13(20):5098.

13. Hu JCC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737-6747.

14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.

15. Soulieres D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323-335.

16. Seiwert TY, Zuo Z, Keck MK, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632-641.

17. van Harten AM, Brakenhoff RH. Targeted treatment of head and neck (pre)cancer: preclinical target identification and development of novel therapeutic applications. Cancers (Basel). 2021;13(11):2774.

18. Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013;73(11):3381-3392.

19. Weaver AN, Cooper TS, Rodriguez M, et al. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget. 2015;6(29):26995-27007.

20. Zhou L, Cha G, Chen L, Yang C, Xu D, Ge M. Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer Metastasis Rev. 2021;40(1):141-152.

21. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127-136.

22. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - a case matched analysis. Radiother Oncol. 2016;120(1):48-55.

23. Vargo JA, Ferris RL, Ohr J, et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015;91(3):480-488.

24. Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83(3):986-993.

25. International Atomic Energy Agency. New radiotherapy technique for treating head and neck cancer could reduce treatment times by nearly half. IAEA News. May 7, 2024.

26. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40-50.

27. Bourhis J, Sozzi WJ, Jorge PG, et al. Treatment of a first patient with FLASH-radiotherapy. Radiother Oncol. 2019;139:18-22.

28. Tinganelli W, Durante M. Biomedical applications of charged particle radiation: genomics and beyond. Br J Radiol. 2020;93(1107):20190329.

29. de Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1043-1051.

30. Civantos FJ, Zitsch RP, Schuller DE, et al. Sentinel lymph node biopsy for squamous cell carcinoma of the head and neck. J Clin Oncol. 2010;28(14):2358-2365.

31. van Keulen S, Nishio N, Fakurnejad S, et al. The clinical application of fluorescence-guided surgery in head and neck cancer. J Nucl Med. 2019;60(6):758-763.

32. Numajiri T, Nakamura H, Sowa Y, Nishino K. Low-cost design and manufacturing of surgical guides for mandibular reconstruction using a fibula. Plast Reconstr Surg Glob Open. 2016;4(7):e805.

33. Profeta AC, Schilling C, McGurk M. Augmented reality visualization in head and neck surgery: an overview of recent findings in sentinel node biopsy and future perspectives. Br J Oral Maxillofac Surg. 2016;54(6):694-696.

34. Seikaly H, Biron VL, Funk GF. Microsurgical free tissue transfer in head and neck reconstruction: the University of Alberta experience. Head Neck. 2019;41(1):24-29.

35. Chauvet P, Collins T, Debize C, et al. Augmented reality in a tumor resection model. Surg Endosc. 2018;32(3):1192-1201.

36. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.

37. Weiss J, Sheth S, Deal AM, et al. Concurrent definitive immunoradiotherapy for patients with locally advanced head and neck cancer and increased risk of recurrence after standard chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2022;112(4):897-907.

38. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928.

39. Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450-462.

40. Haddad RI, Seiwert TY, Chow LQM, et al. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma. J Clin Oncol. 2021;39(15_suppl):6009.

41. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550.

42. Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23(7):1447-1454.

43. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20(7):1747-1756.

44. Jiang W, von Roemeling CA, Chen Y, et al. Designing nanomedicine for immuno-oncology. Nat Biomed Eng. 2017;1(2):0029.

45. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.

46. Snipstad S, Sulheim E, de Lange Davies C, et al. Sonoporation of drug delivery to tumors. Expert Opin Drug Deliv. 2018;15(12):1157-1174.

47. Rischin D, Harrington KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15_suppl):6000.

48. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501.

49. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394-1403.

50. Economopoulou P, Kotsantis I, Psyrri A. Tumor microenvironment and immunotherapy response in head and neck cancer. Cancers (Basel). 2020;12(11):3377.

51. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.

52. Hoadley KA, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304.e6.

53. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-137.

54. Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35(5):490-497.

55. Aggarwal C, Cohen RB, Morrow MP, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res. 2019;25(1):110-124.

56. Masterson L, Lechner M, Loewenbein S, et al. CD8+ T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer. Eur J Cancer. 2016;67:141-151.

57. Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158-168.
</EXAMPLE_E>
